Bioactive Compound Identification via Structural–Activity Correlation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for identifying bioactive compounds are time-consuming and expensive, often requiring tedious isolation and analysis of multiple fractions, and are hindered by issues like antimicrobial resistances, necessitating a need for high-throughput and automated processes.

Innovation Solution

A method involving chromatographic separation, structural analysis, and bioactivity profiling of fractionated sample flows using microfluidic devices, particularly paper-based ones, to rapidly identify bioactive compounds by correlating structural and bioactivity profiles, enabling high-throughput and automated detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional isolation and analysis methods are used, then measurement precision is improved, but productivity deteriorates

Engineering Contradiction:
Improveidentification accuracyVSAvoididentification speed
Core Design Contradiction:
Measurement precisionVSProductivity

Solution Approach 1:

The sample flow is divided into multiple fractions through chromatographic separation, with each fraction analyzed independently for bioactivity and structural characteristics. This segmentation enables parallel processing of multiple samples simultaneously, dramatically increasing throughput while maintaining precise identification of individual bioactive compounds

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Chromatographic separation is performed in advance to pre-fractionate the complex mixture into distinct components before bioactivity analysis. This preliminary structural characterization allows subsequent rapid screening of fractions, eliminating the need for time-consuming isolation and re-analysis of active compounds

Inventive Principle:
Principle #10Preliminary action

2Measurement precision

If multiple fractions are collected and analyzed, then measurement precision is improved, but loss of time worsens

Engineering Contradiction:
Improveidentification accuracyVSAvoidanalysis duration
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The system implements continuous chromatographic separation with real-time fraction collection and immediate bioactivity analysis. The automated flow-through system eliminates idle time between sampling steps, maintaining continuous analytical action from sample injection through identification, thereby reducing total analysis time while preserving accurate compound characterization

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

Structural analysis via chromatography is performed preliminarily to pre-identify and fractionate compounds before bioactivity testing. This advance structural characterization allows direct correlation of structural data with bioactivity results, eliminating subsequent time-consuming isolation and analysis steps

Inventive Principle:
Principle #10Preliminary action

3Measurement precision

If intermediate storage of fractions is performed, then measurement precision is improved, but object-generated harmful factors worsen

Engineering Contradiction:
Improveidentification accuracyVSAvoidsample degradation
Core Design Contradiction:
Measurement precisionVSObject-generated harmful factors

Solution Approach 1:

Chromatographic separation and structural characterization are performed in advance before bioactivity analysis. This preliminary structural mapping allows immediate identification and tracking of bioactive fractions through correlation of retention times and mass spectral data, eliminating the need for intermediate storage and preventing sample degradation during storage periods

Inventive Principle:
Principle #10Preliminary action

4Productivity

If automated high-throughput methods are implemented, then productivity is improved, but device complexity worsens

Engineering Contradiction:
Improveidentification throughputVSAvoidsystem complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The system merges chromatographic separation, mass spectrometric detection, and bioactivity analysis into an integrated automated platform. By combining these functions into a single hyphenated system with automated fraction collection and data correlation, high throughput is achieved while the complexity is managed through unified control architecture rather than separate manual operations

Inventive Principle:
Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Accelerates the identification of bioactive compounds by integrating structural and bioactivity analysis, reducing the need for intermediate storage and minimizing sample degradation, while enhancing sensitivity and specificity through automated correlation of chromatographic and mass spectrometric data.

Implementation Method 1

Chromatographic separation of the sample for generating a fractionated sample flow

Methodology Applied
Scientific EffectChromatography: Chromatography

Data Source

PatentEP4624922A1Method and device for identifying bioactive compounds
Publication Date: 2025.10.01 EBERHARD KARLS UNIVERSITAET TUEBINGEN
  • EP4624922A1 patent drawingFigure 1~2
  • EP4624922A1 patent drawingFigure 3A~3F
  • EP4624922A1 patent drawingFigure 4A~4C

AI summary

The present invention provides a method and a device for identifying bioactive compounds complex mixtures. The method includes provision of a sample that may comprise at least one bioactive compound. The method further includes a chromatographic separation of the sample for generating a fractionated sample flow (11). The fractionated sample flow (11) is split into a first fractionated sample flow (21) and a second fractionated sample flow (22). The method further includes a structural analysis of the first fractionated sample flow (21) for generating a structural profile (400) of the first fractionated sample flow. Further, the method includes a bioactivity analysis of the second fractionated sample flow (22) for generating a bioactivity profile (400) of the second fractionated sample flow. The structural profile (400) of the first fractionated sample flow (21) and the bioactivity profile (400) of the second fractionated sample flow (22) are correlated in order to detect and assign bioactive compounds within the fractionated sample flow.